Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
FundPlus is a private foundation established in May 2015 by Désiré Collen and the non-profit organization Life Sciences Research Partners. Based in Leuven, Belgium, it operates as a Belgian Naamloze Vennootschap/Société Anonyme (NV/SA). The fund is dedicated to long-term equity investments in innovative life sciences companies, primarily focusing on therapeutics, diagnostics, and medical devices. FundPlus has raised €200 million in financing commitments, positioning itself as a significant player in the European venture capital landscape.
Since its inception, FundPlus has aimed to create sustainable shareholder value while contributing positively to the development of the life sciences sector and society at large. The firm’s commitment to societal impact is evident in its investment strategy, which emphasizes innovative healthcare solutions. FundPlus currently manages a portfolio of seven companies, reflecting its focus on supporting growth in the life sciences sector.
FundPlus invests in innovative life sciences companies that are primarily active in therapeutics, diagnostics, and medical devices. The fund targets companies seeking Series A or B financing that have already achieved proof of concept. The intended investment size per company ranges from €5 million to €15 million, distributed over various milestones. FundPlus aims to be a significant minority shareholder, holding more than 10% of equity, and actively participates as a board member in its portfolio companies.
The firm focuses its investments in Europe, particularly Belgium, and seeks to partner with companies that demonstrate potential for sustainable growth and societal impact. FundPlus emphasizes a collaborative approach, providing strategic guidance and support to help portfolio companies achieve their milestones and grow sustainably. This investment strategy aligns with the firm’s mission to contribute positively to the life sciences sector.
FundPlus has a notable portfolio that includes seven companies, each contributing to advancements in the life sciences sector:
Caroline Goddeeris: Partner at FundPlus, Caroline has extensive experience in venture capital and life sciences. She has been instrumental in guiding portfolio companies through their growth phases.
Bart De Leeuw: Partner and CFO, Bart brings financial expertise to the firm, overseeing fund operations and financial strategy. His background includes significant roles in financial management within the biotech sector.
Halina Novak: Partner at FundPlus, Halina specializes in investment strategy and portfolio management, focusing on identifying high-potential life sciences companies.
Patrick Vanbeneden: Consultant, Patrick provides strategic insights and industry connections to enhance the firm's investment approach and portfolio performance.
Diane De Wyngaert: Administrative Assistant, Diane supports the operational aspects of FundPlus, ensuring smooth communication and coordination within the team.
To pitch to FundPlus, founders should send an email to info@fundplus.be. It is recommended to include a comprehensive pitch deck that outlines the business model, market analysis, and financial projections. FundPlus appreciates clarity and detail in presentations.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are preferred, as they can facilitate a more favorable review process.
As of March 2026, FundPlus continues to expand its portfolio in the life sciences sector, maintaining a focus on innovative companies. The firm has recently made investments in several promising startups, including Minoryx and AstriVax Therapeutics, which are at the forefront of developing groundbreaking therapies.
FundPlus's commitment to societal impact is reflected in its ongoing support for companies that aim to address critical healthcare challenges. The firm remains active in the European venture capital scene, leveraging its €200 million AUM to back companies that align with its mission.
What are FundPlus's investment criteria?
FundPlus invests in innovative life sciences companies primarily in therapeutics, diagnostics, and medical devices. They target Series A and B financing for companies that have achieved proof of concept.
How can I apply or pitch to FundPlus?
Founders can pitch to FundPlus by sending an email to info@fundplus.be. It is advisable to include a detailed business plan and financial projections in the pitch.
What makes FundPlus different from other venture capital firms?
FundPlus distinguishes itself through its commitment to societal impact alongside shareholder value. The firm actively participates as a board member in its portfolio companies, providing strategic guidance and support.
What is the geographic scope of FundPlus's investments?
FundPlus primarily focuses on investments in Europe, with a strong emphasis on Belgium. This regional focus allows them to leverage local expertise and networks.
What is the typical fund size and check size for FundPlus?
FundPlus has raised €200 million in financing commitments, with typical check sizes ranging from €5 million to €15 million per investment.
What is FundPlus's post-investment involvement like?
FundPlus takes significant minority stakes in its portfolio companies and plays an active role as a board member, helping guide strategic decisions and support growth initiatives.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.